For instance, the safety and tolerability of different doses of AZD2693, a potent patatin-like phospholipase domain-containing 3 (PNPLA3) GalNac-ASO, applied subcutaneously in patients with MASH (NASH), fibrosis Stage 0 to 3, and carriers of the PNPLA3 I48M Risk Alleles, was tested (NCT04483947, clinicalgov.it last accessed on 9 December 2024). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatohepatitis.